Niewydolność serca: badanie kliniczne fazy IV
Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
Aktualnie w Polsce jest 36 badań klinicznych w obszarze: nadciśnienie tętnicze (34 rekrutują, 2 wkrótce zaczną rekrutację). Badania prowadzą ośrodki w 59 miastach, m.in. Kraków, Poznań, Warszawa, Wrocław.
Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
Updated Abdominal Compartment Society Consensus Definitions
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Portal Inflow Modulation Prior to Liver Transplantation in Patients With Increased Risk of Intraoperative Blood Loss
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic…
Overnight Dexamethasone in Primary Aldosteronism Screening
Telemedical Algorithm-Supported Care for Hypertension
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Optimal Medical Treatment of Difficult-to-treat Hypertension
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Novel Setup Algorithm for Cardiac Neuromodulation Therapy
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
HIIT vs MICT During Pregnancy and Health and Birth Outcomes in Mothers and Children
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
Według daty pojawienia się badania w rejestrze (CTIS lub ClinicalTrials.gov).
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań w obszarze: nadciśnienie tętnicze możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.